Close Menu

Diagnostics Business, Policy & Funding

Breaking news on Diagnostics business, policy & funding.

The company is also developing two SARS-CoV-2 tests, including a rapid point-of-care test that is expected to be fully developed within the next two months.

The firm said the BARDA funding will support scale-up of a molecular test to facilitate management of the coronavirus pandemic cycle.

The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.

The analyzer supports COVID-19 response efforts, where blood-gas testing plays a critical role in monitoring patients' respiratory distress, the firm said.

The Aries SARS-CoV-2 assay provides results in approximately two hours and can be run on Luminex's sample-to-answer Aries Systems.